As we mentioned above, four ASOs designed to skip exons 51 (eteplirsen), 53 (golodirsen and viltolarsen) and exon 45 (casimersen) of dystrophin mRNA seem to promote dystrophin restoration in DMD patients, and they have been conditionally approved by the FDA [13,14,15,16]. Here, DMD is linked to Duchenne muscular dystrophy.